Epidemiology and treatment of mucormycosis

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1163-1175

  Lewis, Russell E ^a   Kontoyiannis, Dimitrios P ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Mucorales; mucormycosis; risk factors; treatment; zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ECHINOCANDIN; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; GENE SEQUENCE; HUMAN; MUCORMYCOSIS; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TAXONOMY; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; COMBINED MODALITY THERAPY; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MUCORALES; MUCORMYCOSIS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84884151249     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.78     Document Type: Review

References (81)

1. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 98(4), 492-504 (2012).
2. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based front-line therapy significantly increases mortality in hematologic malignancy patients with zygomycosis. Clin. Infect. Dis. 47(4), 503-509 (2008).
3. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Archiv. Intern. Med. 159(12), 1301-1309 (1999).
4. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191(8), 1350-1360 (2005).
5. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005).
6. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob. Agents Chemother. 55(11), 5018-5021 (2011).
7. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin. Infect. Dis. 54(Suppl. 1), S8-S15 (2012).
8. Hibbett DS, Binder M, Bischoff JF et al. A higher-level phylogenetic classification of the fungi. Mycological Res. 111(Pt 5), 509-547 (2007).
9. Ma LJ, Ibrahim AS, Skory C et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 5(7), e1000549 (2009).
10. Etienne KA, Gillece J, Hilsabeck R et al. Whole genome sequence typing to investigate the apophysomyces outbreak following a tornado in Joplin, Missouri, 2011. PLoS ONE 7(11), e49989 (2012).
11. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin. Infect. Dis. 54(Suppl. 1), S67-S72 (2012).
12. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N. Engl. J. Med. 299(20), 1115-1118 (1978).
13. Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection: occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA 242(3), 272-274 (1979).
14. Paparello SF, Parry RL, MacGillivray DC, Brock N, Mayers DL. Hospital-acquired wound mucormycosis. J. Infect. Dis. 14, 390-392 (1992).
15. Chakrabarti A, Kumar P, Padhye AA et al. Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Clin. Infect. Dis. 24(4), 580-583 (1997).
16. Jain JK, Markowitz A, Khilanani PV, Lauter CB. Localized mucormycosis following intramuscular corticosteroid: case report and review of the literature. Am. J. Med. Sci. 275(2), 209-216 (1978).
17. Verweij PE, Voss A, Donnelly JP, De Pauw BE, Meis JF. Wooden sticks as the source of a pseudoepidemic of infection with Rhizopus microsporus var. Rhizopodiformis among immunocompromised patients. J. Clin. Microbiol. 35(9), 2422-2423 (1997).
18. Paydas S, Yavuz S, Disel U et al. Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: a possible relation with use of a tongue depressor. Am. J. Med. 114(7), 618-620 (2003).
19. Kurukularante C, Garcia-Diaz J, Reed D, Chapman J, Kemmerly S. Beyond Rhizopus and Mucor: hurricane Katrina stirs up Synephalastrum in New Orleans. Presented at: Focus Fungal Infections 16. Las Vegas, NV, USA, 8-10 March 2006.
20. Neblett Fanfair R, Benedict K, Bos J et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N. Engl. J. Med. 367(23), 2214-2225 (2012).
21. Andresen D, Donaldson A, Choo L et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 365(9462), 876-878 (2005).
22. Warkentien T, Rodriguez C, Lloyd B et al. Invasive mold infections following combat-related injuries. Clin. Infect. Dis. 55(11), 1441-1449 (2012).
23. Bearer EA, Nelson PR, Chowers MY, Davis CE. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J. Clin. Microbiol. 32(7), 1823-1824 (1994).
24. Holland J. Emerging zygomycoses of humans: Saksenaea vasiformis and Apophysomyces elegans. Curr.Top. Med. Mycol. 8(1-2), 27-34 (1997).
25. Lawson HH, Schmaman A. Gastric phycomycosis. Br. J. Surg. 61(9), 743-746 (1974).
26. Neame P, Rayner D. Mucormycosis: a report on twenty-two cases. Arch. Pathol. 70, 143-150 (1960).
27. Cheng VC, Chan JF, Ngan AH et al. Outbreak of intestinal infection due to Rhizopus microsporus. J. Clin. Microbiol. 47(9), 2834-2843 (2009).
28. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus,-Mucor, and-Lichtheimia species. Clin. Microbiol. Rev. 24(2), 411-445 (2011).
29. Goel P, Jain V, Sengar M, Mohta A, Das P, Bansal P. Gastrointestinal mucormycosis: a success story and appraisal of concepts. J. Infect. Public Health 6(1), 58-61 (2013).
30. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin. Infect. Dis. 27(5), 1138-1147 (1998).
31. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 54(Suppl. 1), S23-S34 (2012).
32. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the annual of the pathological autopsy cases in Japan in 1993 and 1997. Pathol. Int. 53(11), 744-750 (2003).
33. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg. Infect. Dis. 15(9), 1395-1401 (2009).
34. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (Transnet) database. Clin. Infect. Dis. 50(8), 1091-1100 (2010).
35. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet). Clin. Infect. Dis. 50(8), 1101-1111 (2010).
36. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350(9), 950-952 (2004).
37. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 40(5), 451-456 (2007).
38. Chakrabarti A, Singh R. The emerging epidemiology of mould infections in developing countries. Curr. Opin. Infect. Dis. 24(6), 521-526 (2011).
39. Rammaert B, Lanternier F, Poiree S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 38(3), 193-204 (2012).
40. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin. Infect. Dis. 54(Suppl. 1), S35-S43 (2012).
41. Boelaert JR, Van Cutsem J, De Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 45(3), 667-671 (1994).
42. Boelaert JR, De Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J. Clin. Invest. 91, 1979-1986 (1993).
43. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18(3), 556-569 (2005).
44. Liu M, Spellberg B, Phan QT et al. The endothelial cell receptor grp78 is required for mucormycosis pathogenesis in diabetic mice. J. Clin. Invest. 120(6), 1914-1924 (2010).
45. Ibrahim AS, Gebremariam T, Lin L et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol. Microbiol. 77(3), 587-604 (2010).
46. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin. Infect. Dis. 54(Suppl. 1), S16-S22 (2012).
47. Artis WM, Patrusky E, Rastinejad F, Duncan RL Jr. Fungistatic mechanism of human transferrin for Rhizopus oryzae and trichophyton mentagrophytes: alternative to simple iron deprivation. Infect. Immun. 41(3), 1269-1278 (1983).
48. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 31(12), 1109-1114 (1982).
49. Ibrahim AS, Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117(9), 2649-2657 (2007).
50. Chamilos G, Lewis RE, Hu J et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc. Natl Acad. Sci. USA 105(27), 9367-9372 (2008).
51. Soummer A, Mathonnet A, Scatton O et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob. Agents Chemother. 52(4), 1585-1586 (2008).
52. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob. Agents Chemother. 50(11), 3968-3969 (2006).
53. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The deferasirox-ambisome therapy for mucormycosis (DEFEAT mucor) study: a randomized, double-blinded, placebo-controlled trial. J. Antimicrob. Chemother. 67(3), 715-722 (2012).
54. Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. J. Antimicrob. Chemother. 67(3), 519-520 (2012).
55. Soman R, Gupta N, Shetty A, Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. J. Antimicrob. Chemother. 67(3), 783-784 (2012).
56. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30(6), 851-856 (2000).
57. Gupta K, Nada R, Joshi K, Rohilla M, Walia R. Can ascending infection from bladder serve as the portal of entry for primary renal zygomycosis? Mycopathologia 170(5), 357-360 (2010).
58. Kontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of zygomycetes under physiologic temperature conditions. Am. J. Clin. Pathol. 127(2), 208-212 (2007).
59. Tarrand JJ, Lichterfeld M, Warraich I et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am. J. Clin. Pathol. 119(6), 854-858 (2003).
60. Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 117(1), 279-282 (2000).
61. Walsh TJ, Gamaletsou MN, Mcginnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin. Infect. Dis. 54(Suppl. 1), S55-S60 (2012).
62. Millon L, Larosa F, Lepiller Q et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin. Infect. Dis. 56(10), e95-e101 (2013).
63. Greenberg MR, Lippman SM, Grinnell VS, Colman MF, Edwards JE Jr. Computed tomographic findings in orbital mucor. West J. Med. 143(1), 102-103 (1985).
64. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol. Clin. N. Amer. 33(2), 349-365 (2000).
65. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin. Infect. Dis. 41(1), 60-66 (2005).
66. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 118(5), 1216-1224 (2011).
67. Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. Curr. Opin. Infect. Dis. 24(4), 309-314 (2011).
68. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 40(Suppl. 6), S401-S408 (2005).
69. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27(12), 1627-1636 (2007).
70. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44(1), 2-12 (2007).
71. Verweij PE, Gonzalez GM, Wiedrhold NP et al. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J. Chemother. 21(3), 272-281 (2009).
72. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob. Agents Chemother. 52(4), 1556-1558 (2008).
73. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49(2), 721-727 (2005).
74. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clin. Infect. Dis. 47(2), 226-235 (2008).
75. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 47(3), 364-371 (2008).
76. Raj P, Vella EJ, Bickerton RC. Successful treatment of rhinocerebral mucormycosis by a combination of aggressive surgical debridement and the use of systemic liposomal amphotericin B and local therapy with nebulized amphotericin-a case report. J. Laryngol. Otol. 112(4), 367-370 (1998).
77. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg. 57(4), 1044-1050 (1994).
78. Schmidt S, Tramsen L, Perkhofer S et al. Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity. Immunobiology 218(7), 939-944 (2012).
79. Schmidt S, Tramsen L, Perkhofer S et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J. Infect. Dis. 206(1), 135-139 (2012).
80. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J. Infect. Dis. 191(7), 1180-1187 (2005).
81. Barratt DM, Van Meter K, Asmar P et al. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model. Antimicrob. Agents Chemother. 45(12), 3601-3602 (2001).